1. Short title This Act may be cited as the Pharmaceutical Supply Chain Security Act . 2. Reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on the People's Republic of China (a) Report on pharmaceuticals imported from the People's Republic of China (1) In general Not later than 180 days after the date of the enactment of this Act, the Commissioner of Food and Drugs, in consultation with the United States Trade Representative, shall submit to the appropriate congressional committees a report that sets forth a list of— (A) each finished pharmaceutical product that is imported into the United States from the People’s Republic of China in a quantity that exceeds 20 percent of the quantity of the product available for use in the United States; and (B) each active pharmaceutical ingredient that is imported into the United States from the People’s Republic of China in a quantity that exceeds 20 percent of the quantity of the ingredient available for use in the United States. (2) Confidential The report required by paragraph (1) shall be confidential and may not be disclosed to the public. (b) Strategy for pharmaceutical supply chain resiliency (1) In general The President shall develop a comprehensive strategy to address the national security threat posed by the control by the People’s Republic of China of the global supply of finished pharmaceutical products and active pharmaceutical ingredients. (2) Elements The strategy required by paragraph (1) shall include efforts to develop a more reliable and secure supply chain for finished pharmaceutical products and active pharmaceutical ingredients, including manufacturing and production projects that— (A) contribute to the development of a more reliable and secure supply chain for such products and ingredients; (B) reduce reliance on the People’s Republic of China for such products and ingredients